MedRhythms, a Portland-based company that combines sensors, neuroscience and music to help people recover from neurologic injury or disease, announced Friday it raised $5 million in an oversubscribed Series A Financing round. The company stated in a news release that it intended to raise $4 million but due to substantial interest it raised the offering to $5.3 million. By the time of Friday’s announcement, it had raised $5 million. This investment will allow MedRhythms to develop and launch a patent-pending digital therapeutics platform that focuses on building evidence-based, FDA-approved, prescription products for people with neurologic injuries and diseases to improve and measure walking. While the first product on the platform focuses on the post-stroke population, the pipeline includes products for Parkinson’s disease, multiple sclerosis, aging-In-place and traumatic brain injury. Read more here.
MedRhythms, a Portland-based company that combines sensors, neuroscience and music to help people recover from neurologic injury or disease, exceeds $4M goal in Series A financing round
Related Posts
Bar Harbor approves Jackson Lab’s $33M expansion for rare disease research
The Bar Harbor Planning Board has approved a plan by the Jackson Laboratory to build a 20,000-square-foot expansion to its Rare Disease Translational...
Bigelow lab receives $7 million for algae research, business development
Researchers at Bigelow Laboratory for Ocean Sciences believe algae can make a big splash in the agricultural, aquaculture and pharmaceutical industries,...
Should Maine create a public medical school? UMaine System will study the question
The University of Maine System said this week it will work with a national consultant to study the feasibility of launching the state’s...